Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476725 | 1.00 | EPHX1 (0.47) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL459574 | 1.00 | EPHX1 (0.47) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| Hydrochloric Acid SCHEMBL10476064 | 0.98 | EPHX1 (0.46) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL2494230 | 0.95 | EPHX1 (0.55) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL2494231 | 0.95 | EPHX1 (0.55) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL7616231 | 0.93 | MME (0.42) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL16124605 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL7770681 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL16124602 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL7770680 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429354-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | Chromadex Inc. (US) | 2019-01-23 | — | — | EP | claimed |
| WO-2017161165-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | WO | claimed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-1307226-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-111728444-A | Sleeping bag | 秦皇岛九零一五科技有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-110526903-A | Bisindole maleimide derivative and its preparation method and application | OCEAN UNIV CHINA | 2019-12-03 | — | — | CN | disclosed |
| CN-110218206-A | Bisindole maleimide derivative and its preparation method and application | 中国海洋大学 | 2019-09-10 | — | — | CN | disclosed |
| EP-0351856-A2 | Thiazolo[5,4-b]azepine compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0346208-A1 | 4-Amino quinolines and naphthyridines, process for their preparation and their use as medicaments | ELF SANOFI (FR) | 1989-12-13 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4618710-A | Preparation of optically active ketones | THE REGENTS OF THE UNIVERSITY OF CALIF. (US) | 1986-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | EPHX1 3512/4885SMN1; SMN2 3054/4885NPC1 979/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | EPHX1 988/4885SMN1; SMN2 2947/4885NPC1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.